Context Therapeutics Inc. (NASDAQ:CNTX) Receives $5.25 Average Price Target from Analysts

Shares of Context Therapeutics Inc. (NASDAQ:CNTX) have been given a consensus recommendation of “Buy” by the six ratings firms that are covering the stock, MarketBeat reports. Five investment analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $5.25.

A number of equities analysts have issued reports on the company. HC Wainwright lowered their price target on Context Therapeutics from $5.00 to $4.00 and set a “buy” rating on the stock in a research report on Thursday, August 7th. William Blair reiterated an “outperform” rating on shares of Context Therapeutics in a research report on Tuesday, April 29th. D. Boral Capital reiterated a “buy” rating and set a $9.00 price target on shares of Context Therapeutics in a research report on Thursday, August 7th. Finally, Piper Sandler reiterated an “overweight” rating and set a $4.00 price target (down previously from $4.50) on shares of Context Therapeutics in a research report on Thursday, June 26th.

Insider Buying and Selling

In other news, CFO Jennifer Lynn Minai-Azary bought 40,010 shares of the firm’s stock in a transaction dated Friday, June 6th. The shares were acquired at an average price of $0.64 per share, for a total transaction of $25,606.40. Following the completion of the transaction, the chief financial officer directly owned 80,010 shares in the company, valued at $51,206.40. The trade was a 100.03% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Martin A. Lehr bought 100,000 shares of the firm’s stock in a transaction dated Monday, June 9th. The stock was purchased at an average price of $0.70 per share, for a total transaction of $70,000.00. Following the transaction, the chief executive officer owned 920,190 shares of the company’s stock, valued at approximately $644,133. This represents a 12.19% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired 160,010 shares of company stock worth $107,206 in the last quarter. 3.04% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Context Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Jane Street Group LLC acquired a new stake in shares of Context Therapeutics in the fourth quarter valued at approximately $29,000. Citadel Advisors LLC acquired a new stake in shares of Context Therapeutics in the fourth quarter valued at approximately $31,000. Shay Capital LLC acquired a new stake in shares of Context Therapeutics in the fourth quarter valued at approximately $52,000. Walleye Capital LLC increased its holdings in shares of Context Therapeutics by 51.7% in the fourth quarter. Walleye Capital LLC now owns 166,306 shares of the company’s stock valued at $175,000 after purchasing an additional 56,651 shares during the last quarter. Finally, Millennium Management LLC increased its holdings in shares of Context Therapeutics by 24.2% in the fourth quarter. Millennium Management LLC now owns 178,718 shares of the company’s stock valued at $188,000 after purchasing an additional 34,835 shares during the last quarter. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Context Therapeutics Stock Up 6.8%

Shares of CNTX opened at $0.79 on Friday. Context Therapeutics has a 52 week low of $0.49 and a 52 week high of $2.70. The company has a market capitalization of $70.53 million, a price-to-earnings ratio of -2.18 and a beta of 1.89. The stock’s 50-day moving average price is $0.70 and its 200-day moving average price is $0.75.

Context Therapeutics (NASDAQ:CNTX) last issued its earnings results on Wednesday, August 6th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.03). As a group, equities analysts anticipate that Context Therapeutics will post -0.51 EPS for the current fiscal year.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.